Analyzing data from 11 trials from a recent Cochrane review, this study compared MMS to IFA, delivering either 30 or 60 mg of iron, in sustaining hemoglobin and preventing third-trimester anemia and iron deficiency anemia (IDA), accounting for daily iron dose, total supplemental iron intake, and baseline prevalence of anemia. There were no differences between MMS and IFA in third-trimester hemoglobin concentration or risks of anemia or IDA by iron dose or total supplemental iron consumed. Results showed that compared to IFA, MMS results in comparable hemoglobin concentration and protection against anemia during pregnancy, independently of iron dose.
